Executive Summary
Recursion Pharmaceuticals has emerged as a leading clinical-stage TechBio company applying artificial intelligence, automation, and large-scale biological data to transform drug discovery and development. Through a growing network of strategic collaborations with Exscientia, NVIDIA, Bayer, Roche, Sanofi, Merck KGaA, Google Cloud, and Helix, Recursion has built one of the most expansive AI-enabled discovery ecosystems in biopharma.
By 2025, the company’s combined internal and partnered pipeline represents more than $20 billion in potential milestone value, positioning Recursion as a central platform player in the convergence of AI and pharmaceutical R&D.
AI as the Core Operating System
Recursion’s strategy is anchored in its proprietary Recursion OS, an integrated platform combining high-throughput automated biology, massive proprietary datasets, and machine-learning models designed to uncover novel disease biology.
The platform enables:
- Rapid hypothesis generation at biological scale
- AI-driven target and pathway discovery
- Translation of insights into clinical-stage therapeutic programs
This system-level approach allows Recursion to operate simultaneously as a drug developer and a discovery infrastructure provider to partners.
Landmark Combination with Exscientia
In 2024, Recursion entered into a definitive agreement to combine with Exscientia, creating a global AI-first drug discovery company spanning biology, chemistry, and clinical development. The combination expanded Recursion’s chemistry and translational capabilities and significantly increased pipeline density.
The combined entity is expected to deliver approximately 10 clinical readouts over an 18-month period, with near-term milestone opportunities estimated at ~$200 million and aggregate long-term partner value exceeding $20 billion, excluding royalties.
Major Biopharma and Technology Collaborations
Recursion’s collaboration portfolio spans pharmaceutical innovation and advanced computing:
- Bayer Precision Oncology Collaboration
Recursion and Bayer expanded their research alliance to focus on precision oncology, combining Bayer’s medicinal chemistry expertise with Recursion’s AI discovery platform. The collaboration includes development of multiple oncology programs with potential milestone and royalty value exceeding $1.5 billion. - Roche and Genentech Research Collaboration
The company continues to work with Roche and Genentech across neuroscience and oncology programs, applying AI-enabled phenomics to uncover novel therapeutic mechanisms. - Sanofi Strategic Research Alliance
Recursion’s long-standing partnership with Sanofi spans oncology and immunology, with cumulative milestone and royalty potential in the multi-billion-dollar range. - Merck KGaA Multi-Year Collaboration
Recursion collaborates with Merck KGaA on AI-driven discovery programs in oncology and immunology, expanding its European footprint and translational reach. - Helix Clinico-Genomic Data Partnership
A multi-year collaboration with Helix provides access to population-scale, de-identified clinico-genomic data to train AI models for target discovery, biomarker development, and patient stratification. - Google Cloud Strategic Expansion
Recursion’s expanded partnership with Google Cloud supports large-scale computing, AI model development, and generative AI exploration across its discovery workflows. - NVIDIA Strategic Investment and Collaboration
NVIDIA made a $50 million strategic investment in Recursion to support development of AI foundation models for biology and chemistry, leveraging accelerated computing infrastructure.
Capital Strength and Pipeline Momentum
The combination with Exscientia strengthened Recursion’s capital position while expanding its end-to-end discovery-to-clinic capabilities. The company continues to advance internal programs across rare diseases, oncology, immunology, and infectious disease, with several candidates approaching key clinical milestones.
This dual strategy—internal asset development and large-scale partnered discovery—positions Recursion to capture value both through pipeline ownership and long-term collaboration economics.
Strategic Positioning in AI Biopharma
Recursion differentiates itself through scale, integration, and partnership breadth. Unlike platform-only AI companies, Recursion operates as both a technology provider and a clinical-stage drug developer, aligning AI insights directly with patient outcomes.
As pharmaceutical companies increasingly seek AI systems that can deliver validated biology and executable programs, Recursion’s model represents a potential blueprint for AI-native drug development.
Outlook
By 2025, Recursion Pharmaceuticals stands as a defining example of how AI, data, and automation can be integrated across the drug discovery lifecycle. With partnerships spanning major pharmaceutical companies and leading technology providers—and with more than $20 billion in potential collaboration value—Recursion is positioned to shape the next era of AI-enabled medicine discovery and development.
By